Top 10 Best-Selling Drugs Of Q3 2023: Ozempic Challenges Humira As Keytruda Extends Leadership
COVID-19 Products Are Notable By Their Absence
As Merck & Co’s checkpoint inhibitor Keytruda further cemented its position at the top of the best-selling drugs list, biosimilar-challenged Humira sales fell once again. Meanwhile, Novo Nordisk’s diabetes injection Ozempic continued its ascent.
You may also be interested in...
But the Danish group is still bedeviled by supply problems, and much is hanging on upcoming cardiovascular outcomes data.
Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.
The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.